Table of Content:

• Introduction
• The FreeStyle Libre 3 System: A Game-Changer
• The FreeStyle Libre 2 System: A Proven Pioneer
• The Impact on Glycemic Control and Well-Being
• Medicare Coverage: Ensuring Accessibility
• Conclusion

Introduction

Diabetes is a chronic condition that requires diligent management to prevent life-threatening complications. The advent of continuous glucose monitoring (CGM) systems has transformed the lives of millions of individuals living with this condition. Among the trailblazers in this field are the FreeStyle Libre 3 and FreeStyle Libre 2 systems by Abbott, which offer real-time glucose monitoring and are covered by Medicare for eligible beneficiaries.

The FreeStyle Libre 3 System: A Game-Changer

Unparalleled Convenience and Discretion

The FreeStyle Libre 3 system is the world’s smallest, thinnest, and most discreet CGM sensor. Its cutting-edge technology automatically sends glucose readings every minute to a compatible smartphone or reader, eliminating the need for scanning. This unprecedented level of convenience and discretion empowers individuals with diabetes to seamlessly integrate glucose monitoring into their daily routines without disruption.

Real-Time Data, Real-Time Control

With the FreeStyle Libre 3 system, users can access real-time glucose data at a glance, enabling proactive decision-making and better management of their condition. The system’s customizable alarms alert users when glucose levels cross predetermined thresholds, allowing for timely interventions and preventing potential complications.

The FreeStyle Libre 2 System: A Proven Pioneer

Painless Glucose Monitoring

While slightly larger than its successor, the FreeStyle Libre 2 system is equally remarkable, offering real-time glucose readings with a painless scan using a reader or compatible smartphone app. This innovative technology eliminates the need for frequent and painful fingersticks, reducing the burden and improving the overall quality of life for individuals with diabetes.

Customizable Alerts for Better Control

Like the FreeStyle Libre 3 system, the FreeStyle Libre 2 system features customizable alarms that alert users when glucose levels cross predetermined thresholds. This feature empowers users to take proactive measures and prevent potential complications, such as hypoglycemia or hyperglycemia.

The Impact on Glycemic Control and Well-Being

Substantial Reductions in HbA1c Levels

A meta-analysis published in Diabetes Therapy in 2020 demonstrated that the use of FreeStyle Libre systems led to substantial reductions in HbA1c levels, a key indicator of long-term glucose control (1). This significant improvement highlights the efficacy of these CGM systems in achieving better glycemic control, reducing the risk of long-term complications associated with diabetes.

Improved Quality of Life

Beyond glycemic control, a study published in BMJ Open Diabetes Research and Care in 2019 revealed that the use of FreeStyle Libre systems improved overall well-being and decreased disease burden among individuals with diabetes after one year of use (4). This finding underscores the positive impact of these CGM systems on the overall quality of life for those living with this chronic condition.

Medicare Coverage: Ensuring Accessibility

The Centers for Medicare & Medicaid Services (CMS) recognizes the value of continuous glucose monitoring in diabetes management. As such, the FreeStyle Libre 3 and FreeStyle Libre 2 systems are covered by Medicare for eligible beneficiaries who meet specific criteria outlined by CMS (2).

Eligibility Criteria

To qualify for Medicare coverage, patient with diabetes must meet the following criteria:

• Diagnosis of diabetes
• Adequate training in CGM use, as determined by a healthcare provider
• Use of insulin or a history of problematic hypoglycemia
• Recent evaluation by a healthcare provider (within 6 months) to confirm eligibility

It’s important to note that Medicare coverage requires a prescription for both the reader and sensors. Patients must meet all the specified criteria to qualify for coverage.

Support and Resources

Abbott’s customer care team is available seven days a week to assist individuals in understanding their coverage and eligibility status for the FreeStyle Libre 3 and FreeStyle Libre 2 systems. Additionally, patients can access educational resources and guidance through the MyFreeStyle program, which provides personalized support and guidance on diabetes management.

Conclusion

The FreeStyle Libre 3 and FreeStyle Libre 2 systems have revolutionized diabetes management by providing real-time glucose data, reducing the burden of frequent fingersticks, and enabling proactive decision-making. With Medicare coverage for eligible beneficiaries, these life-changing technologies are becoming more accessible, empowering individuals to take control of their diabetes and potentially reduce the risk of long-term complications. As a hospital professor, I strongly encourage individuals with diabetes to explore the potential benefits of continuous glucose monitoring and discuss their options with their healthcare providers.

References:

1. Evans, Mark, et al. “The Impact of Flash Glucose Monitoring on Glycaemic Control as Measured by HbA1c: a Meta-analysis of Clinical Trials and Real-World Observational Studies.” Diabetes Therapy 11.1 (2020): 83-95. Web.
2. Local Coverage Determination (LCD) L33822, Glucose Monitors, https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=33822.
3. Data on file. Abbott Diabetes Care, Inc.
4. Fokkert, Marion, et al. “Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4).” BMJ Open Diabetes Research and Care 7 (2019): e000809. Web.